Recent studies in the literature point out that HIV-infected subjects
are affected by depression with a relatively high frequency. The aim o
f this study was to assess the efficacy and tolerability of paroxetine
for the treatment of depression in the context of HIV infection. 15 H
IV-infected subjects (10 patients with a major depressive episode and
5 patients with an adjustment disorder with depressed mood, according
to the DSM IV diagnostic criteria) were administered paroxetine at a d
aily dosage of 20 mg. Depressive symptomatology was monitored by means
of the Hamilton Rating Scale for Depression (HAM-D) at the time of en
rollment and 2 weeks, 4 weeks, and 6 weeks later; at the same times ad
verse effects were recorded. 14 patients completed the study, and all
of these recovered from depression; HAM-D mean scores significantly im
proved from baseline to final assessment, both when all subjects were
considered (ANOVA for repeated measurements: p less than or equal to 0
.0001) and when only patients with a major depressive episode were inc
luded in the statistical analysis (ANOVA for repeated measurements: p
< 0.0001). No significant adverse effects were recorded. Because of it
s efficacy and good tolerability paroxetine seems to be suitable for t
he treatment of depression in the context of HIV infection.